However, systemic CCR2 inhibition did not reduce the number of early circulating cancer cells (eCCCs) (Fig. 6n, Supplementary Table 6) compared to the treatment that blocked the CSF1R, which reduced intra-epithelial macrophages by ~77% (Fig. 3h, Supplementary Table 6). This evidence concerns the gene CSF1R and cancer.